Page 1

May 18 , 2021 Abeona THERAPEUTICS Abeona Therapeutics Reports First Quarter Financial Results Patient enrollment ongoing for EB - 101 pivotal Phase 3 VIITAL ™ study Positive interim MPS III data presented at 1th Annual WORLDSymposium ; additional neurocognitive assessments of patients treated in high dose cohort 3 in MPS IIIA Transpher A study and additional clinical data from MPS IIIB Transpher B study expected in 2021 Strengthened management and board to support the company's focus on driving future growth , enhancing corporate governance , and creating additional shareholder value Conference call scheduled for Tuesday , May 25 , 2021 at 8:30 a.m. ET Abeona NEW YORK and CLEVELAND , May 18 , 2021 ( GLOBE NEWSWIRE ) Therapeutics Inc. ( Nasdaq : ABEO ) , a fully - integrated leader in gene and cell therapy , today announced financial results for the first quarter 2021 and recent business progress . " We are off to a fast start in 2021 , reflecting our intense focus on execution , " said Michael Amoroso , Chief Executive Officer of Abeona . " We are focused on completing enrollment in the EB - 101 Phase 3 pivotal VIITAL TM study , gaining clarity on a regulatory path for ABO - 102 in MPS IIIA , producing the first lot of Abeona - produced clinical grade product for ABO - 102 , and reporting additional neurocognitive and biomarker data from both the ABO - 102 Transpher A and the ABO - 101 Transpher B studies . We also have a robust preclinical pipeline , and we are conducting research assessing AAV capsids with the aim of IND enabling studies in two to three eye indications . Importantly , our focus on building the right talent and experience on our leadership team positions us well to continue to advance our clinical programs toward delivering meaningful milestones later this year . " First Quarter and Recent Highlights Corporate Updates • Appointed Michael Amoroso as President , Chief Executive Officer ( CEO ) and a member of the company's Board of Directors . • Abeona strengthened its Board of Directors with the appointment of four new independent members who bring relevant operational leadership experience with life sciences companies , including in the areas of clinical development , manufacturing of cell therapy and gene therapy products , and corporate and financial compliance , to support the company's focus on driving future growth and creating additional shareholder value . EB - 101 ( Autologous , Gene - Corrected Cell Therapy )